| pubmed-article:20926011 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20926011 | lifeskim:mentions | umls-concept:C0014852 | lld:lifeskim |
| pubmed-article:20926011 | lifeskim:mentions | umls-concept:C0007137 | lld:lifeskim |
| pubmed-article:20926011 | lifeskim:mentions | umls-concept:C0259628 | lld:lifeskim |
| pubmed-article:20926011 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:20926011 | lifeskim:mentions | umls-concept:C0220901 | lld:lifeskim |
| pubmed-article:20926011 | lifeskim:mentions | umls-concept:C1522609 | lld:lifeskim |
| pubmed-article:20926011 | lifeskim:mentions | umls-concept:C1554112 | lld:lifeskim |
| pubmed-article:20926011 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:20926011 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:20926011 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:20926011 | pubmed:dateCreated | 2010-10-7 | lld:pubmed |
| pubmed-article:20926011 | pubmed:abstractText | Protease-activated receptor-2 (PAR-2) is essential for the initiation and development of tumours, suggesting that the detection of PAR-2 expression might serve as a clinical marker in the prediction or diagnosis of clinical outcomes of malignant neoplasia. Using immunohisto chemical methods, this study investigated whether the detection of PAR-2 protein had clinical implications for patients with oesophageal squamous cell carcinoma (OSCC). PAR-2 protein was present at a high level in primary OSCC sites but at a low level in normal oesophageal tissue. The level of PAR-2 protein in tumours was significantly correlated with the clinical stage and histological grade of disease. Patients with tumours highly positive for PAR-2 protein had a significantly worse prognosis than those with lower PAR-2 levels. Thus, the over-expression of PAR-2 is a characteristic feature of OSCC and suggests that the immuno histochemical detection of raised levels of PAR-2 may be a potentially useful prognostic indicator. | lld:pubmed |
| pubmed-article:20926011 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20926011 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20926011 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20926011 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20926011 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20926011 | pubmed:issn | 0300-0605 | lld:pubmed |
| pubmed-article:20926011 | pubmed:author | pubmed-author:LiKK | lld:pubmed |
| pubmed-article:20926011 | pubmed:author | pubmed-author:DAYT DTD | lld:pubmed |
| pubmed-article:20926011 | pubmed:author | pubmed-author:LinNN | lld:pubmed |
| pubmed-article:20926011 | pubmed:author | pubmed-author:WangXX | lld:pubmed |
| pubmed-article:20926011 | pubmed:author | pubmed-author:ZhengY LYL | lld:pubmed |
| pubmed-article:20926011 | pubmed:author | pubmed-author:NamI WIW | lld:pubmed |
| pubmed-article:20926011 | pubmed:author | pubmed-author:LiSlS | lld:pubmed |
| pubmed-article:20926011 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:20926011 | pubmed:volume | 38 | lld:pubmed |
| pubmed-article:20926011 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20926011 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20926011 | pubmed:pagination | 1381-8 | lld:pubmed |
| pubmed-article:20926011 | pubmed:meshHeading | pubmed-meshheading:20926011... | lld:pubmed |
| pubmed-article:20926011 | pubmed:meshHeading | pubmed-meshheading:20926011... | lld:pubmed |
| pubmed-article:20926011 | pubmed:meshHeading | pubmed-meshheading:20926011... | lld:pubmed |
| pubmed-article:20926011 | pubmed:meshHeading | pubmed-meshheading:20926011... | lld:pubmed |
| pubmed-article:20926011 | pubmed:meshHeading | pubmed-meshheading:20926011... | lld:pubmed |
| pubmed-article:20926011 | pubmed:meshHeading | pubmed-meshheading:20926011... | lld:pubmed |
| pubmed-article:20926011 | pubmed:meshHeading | pubmed-meshheading:20926011... | lld:pubmed |
| pubmed-article:20926011 | pubmed:meshHeading | pubmed-meshheading:20926011... | lld:pubmed |
| pubmed-article:20926011 | pubmed:meshHeading | pubmed-meshheading:20926011... | lld:pubmed |
| pubmed-article:20926011 | pubmed:meshHeading | pubmed-meshheading:20926011... | lld:pubmed |
| pubmed-article:20926011 | pubmed:meshHeading | pubmed-meshheading:20926011... | lld:pubmed |
| pubmed-article:20926011 | pubmed:meshHeading | pubmed-meshheading:20926011... | lld:pubmed |
| pubmed-article:20926011 | pubmed:meshHeading | pubmed-meshheading:20926011... | lld:pubmed |
| pubmed-article:20926011 | pubmed:articleTitle | Prognostic value of protease-activated receptor 2 expression in oesophageal squamous cell carcinoma. | lld:pubmed |
| pubmed-article:20926011 | pubmed:affiliation | Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. | lld:pubmed |
| pubmed-article:20926011 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20926011 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:2150 | entrezgene:pubmed | pubmed-article:20926011 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:20926011 | lld:entrezgene |
